Previous 10 | Next 10 |
INDIANAPOLIS , May 10, 2019 /PRNewswire/ -- Calumet Specialty Products Partners, L.P. (NASDAQ: CLMT) (the "Partnership," "Calumet," the "Company," "we," "our" or "us"), a leading independent producer of specialty hydrocarbon and fuel products, today reported results for the first quart...
INDIANAPOLIS , May 1, 2019 /PRNewswire/ -- Calumet Specialty Products Partners, L.P. (NASDAQ: CLMT) (the "Partnership," "Calumet," "we," "our" or "us"), a leading independent producer of specialty hydrocarbon and fuel products, today announced that it plans to report results for the fisca...
With the first quarter complete, re-gauging Calumet Specialty's ( CLMT ) possible last quarter results and gauging early second quarter results is our focus. With $1.45 billion in net debt, a continuation of positive cash flow on quarter by quarter basis is critical for Calumet to remain a via...
On March 7, Calumet Specialty Products ( CLMT ) reported its 4th quarter 2018 results and held a conference call. The company reported an EBITDA number of almost $110 million pro forma capturing the attention of investors and analysts. The extraordinary high EBITDA reflects on the company's ...
Calumet Specialty Products Partners, L.P. (CLMT) Q4 2018 Results Conference Call March 07, 2019 09:00 AM ET Company Participants Joseph Caminiti - Investor Relations Tim Go - Chief Executive Officer West Griffin - Chief Financial Officer Bruce Fleming - Executive Vice President...
Gainers: Bio-Path Holdings (NASDAQ: BPTH ) +201% . Seelos Therapeutics (NASDAQ: SEEL ) +79% . ArQule (NASDAQ: ARQL ) +66% . Altimmune (NASDAQ: ALT ) +60% . Rosetta Stone (NYSE: RST ) +31% . Calumet Specialty Products Partners (NASDAQ: CLMT ) +29% . Cleveland BioLabs (NASDAQ: CB...
Calumet Specialty Products Partners ( CLMT +30.3% ) says that Q4 earnings above expectations, though reported lower sales and production volumes on Y/Y basis More news on: Calumet Specialty Products Partners, L.P., Earnings news and commentary, , Read more ...
The following slide deck was published by Calumet Specialty Products Partners, L.P. in conjunction with their 2018 Q4 earnings Read more ...
Seelos Therapeutics (NASDAQ: SEEL ) +55% on acquisition an exclusive license to intellectual property owned by The Regents of the University of California. More news on: Seelos Therapeutics Inc, Bio-Path Holdings, Inc., Altimmune, Inc., Stocks on the move, Read more ...
Calumet Specialty (NASDAQ: CLMT ): Q4 Non-GAAP EPS of $0.55 beats by $0.41 ; GAAP EPS of $0.23 beats by $0.09 . More news on: Calumet Specialty Products Partners, L.P., Earnings news and commentary, Energy stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Calumet Specialty Products Partners L.P. Company Name:
CLMT Stock Symbol:
NASDAQ Market:
Calumet Specialty Products Partners L.P. Website:
Calumet, Inc. to Release Second Quarter 2024 Earnings on August 9, 2024 PR Newswire INDIANAPOLIS , July 26, 2024 /PRNewswire/ -- Calumet, Inc. (NASDAQ: CLMT) (the "Company," "Calumet," "we," "our" or "us"), announced today that it plans to report results for the ...
Calumet Specialty Products Partners, L.P. Completes Conversion to a C-Corporation PR Newswire Common Stock of Calumet, Inc. to Commence Trading on Nasdaq on Thursday, July 11 INDIANAPOLIS , July 10, 2024 /PRNewswire/ -- July 10, 2024 ...